Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastases
Not Applicable
- Conditions
- central nervous system metastases of non-small cell lung cancer with active EGFR mutations treated with daily dosing erlotinib
- Registration Number
- JPRN-UMIN000004703
- Lead Sponsor
- Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.IIPs 2.drug hypersensitivity reaction with gefitinib or erlotinib 3.high risk of brain herniation by lumbar puncture 4.unsuitable for treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method